Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 12 2019
17 12 2019
Historique:
received:
29
08
2019
accepted:
27
11
2019
entrez:
19
12
2019
pubmed:
19
12
2019
medline:
5
11
2020
Statut:
epublish
Résumé
Circulating levels of fibroblast growth factor-21 (FGF21) start increasing in patients with chronic kidney disease (CKD) since early stages during the cause of disease progression. FGF21 is a liver-derived hormone that induces responses to stress through acting on hypothalamus to activate the sympathetic nervous system and the hypothalamus-pituitary-adrenal endocrine axis. However, roles that FGF21 plays in pathophysiology of CKD remains elusive. Here we show in mice that FGF21 is required to survive CKD but responsible for blood pressure dysregulation. When introduced with CKD, Fgf21
Identifiants
pubmed: 31848393
doi: 10.1038/s41598-019-55643-4
pii: 10.1038/s41598-019-55643-4
pmc: PMC6917750
doi:
Substances chimiques
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19247Références
Int J Mol Sci. 2017 Aug 02;18(8):
pubmed: 28767097
J Clin Invest. 1990 Dec;86(6):1855-61
pubmed: 2254449
J Physiol. 2002 Aug 15;543(Pt 1):337-48
pubmed: 12181304
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7432-7
pubmed: 17452648
J Clin Invest. 2008 Dec;118(12):4014-24
pubmed: 19033670
Nature. 2018 Jan 25;553(7689):461-466
pubmed: 29342138
Eur J Neurosci. 2018 Dec;48(12):3466-3476
pubmed: 30251448
iScience. 2018 Apr 27;2:238-268
pubmed: 30428375
Endocr J. 2016;63(2):119-26
pubmed: 26537094
Elife. 2012 Oct 15;1:e00065
pubmed: 23066506
Cell. 1999 Mar 5;96(5):701-12
pubmed: 10089885
PLoS One. 2016 May 17;11(5):e0155386
pubmed: 27187182
World J Nephrol. 2016 Jan 6;5(1):53-65
pubmed: 26788464
Nat Med. 2013 Sep;19(9):1147-52
pubmed: 23933984
Endocrinology. 2012 Jun;153(6):2689-700
pubmed: 22474187
Mol Endocrinol. 2010 Oct;24(10):2050-64
pubmed: 20667984
J Physiol Sci. 2015 Jul;65(4):311-6
pubmed: 25721502
Mol Biol Rep. 2012 Feb;39(2):1791-9
pubmed: 21625850
Hypertension. 2016 May;67(5):1029-37
pubmed: 26953322
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Cell Metab. 2007 Jun;5(6):415-25
pubmed: 17550777
Hypertens Res. 2017 May;40(5):413-422
pubmed: 27904154
Nat Rev Nephrol. 2019 Jan;15(1):27-44
pubmed: 30455427
Am J Physiol Renal Physiol. 2017 May 1;312(5):F917-F924
pubmed: 28274927
J Am Coll Cardiol. 2011 Sep 6;58(11):1152-61
pubmed: 21884954
Nature. 2018 Jan 25;553(7689):501-505
pubmed: 29342135
J Appl Physiol (1985). 2013 Jan 15;114(2):195-202
pubmed: 23139365
Future Cardiol. 2017 May;13(3):279-296
pubmed: 28581362
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
PLoS One. 2011 Apr 15;6(4):e18398
pubmed: 21525989
J Biol Chem. 2007 Sep 14;282(37):26687-95
pubmed: 17623664
J Biol Chem. 2006 Mar 10;281(10):6120-3
pubmed: 16436388
Front Physiol. 2018 Aug 02;9:1001
pubmed: 30116198
Curr Hypertens Rep. 2013 Jun;15(3):160-6
pubmed: 23595357
J Proteome Res. 2017 Apr 7;16(4):1566-1578
pubmed: 28286957
Kidney Int. 2011 Jun;79(12):1370-8
pubmed: 21389978
Endocrinology. 2018 Feb 1;159(2):763-775
pubmed: 29186377
J Mol Med (Berl). 2010 Apr;88(4):383-90
pubmed: 20012594
J Bone Miner Res. 2004 Mar;19(3):429-35
pubmed: 15040831
PLoS One. 2017 Jun 5;12(6):e0178971
pubmed: 28582462